Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: Dose dependency and modulation of biomarkers

Authors

Ronald A. Lubet, National Cancer InstituteFollow
Yan Lu, Washington University School of Medicine in St. Louis
Ann M. Bode, University of Minnesota
Ming You, Washington University School of Medicine in St. Louis
Zoe M. Verney, University of Alabama - Birmingham
Vernon E. Steele, National Cancer Institute
Reid Townsend, University of Minnesota
M. Margaret Juliana, University of Alabama - Birmingham
Clinton J. Grubbs, University of Alabama - Birmingham

Journal

Oncology Reports

Publication Date

2011

Volume

25

Issue

5

Inclusive Pages

1389-1397

Document Type

Open Access Publication

DOI

10.3892/or.2011.1200

Rights and Permissions

Lubet, R. A., Lu, Y., Bode, A. M., You, M., Verney, Z. M., Steele, V. E., . . . Grubbs, C. J. (2011). Efficacy of the EGFr inhibitor iressa on development of chemically-induced urinary bladder cancers: Dose dependency and modulation of biomarkers. Oncology Reports, 25(5), 1389-1397. DOI: 10.3892/or.2011.1200

Recommended Citation

Lubet, Ronald A.; Lu, Yan; Bode, Ann M.; You, Ming; Verney, Zoe M.; Steele, Vernon E.; Townsend, Reid; Juliana, M. Margaret; and Grubbs, Clinton J., "Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: Dose dependency and modulation of biomarkers." Oncology Reports. 25, 5. 1389-1397. (2011).
https://digitalcommons.wustl.edu/open_access_pubs/2098